NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 5 நாட்களுக்கு முன்இன்று 99 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Hester Bio Q2 Transcript: Standalone PAT Up 131%, Gross Margin at 78%
Hester Biosciences released its earnings conference call transcript for Q2 and H1 FY27. Standalone revenue grew 28% in Q2, with PAT rising 131%, supported by strong gross margins of 78% and EBITDA margins of 35%. Consolidated revenue grew 38% in Q2, led by Poultry Healthcare rising 27% and Animal Healthcare rising 34%. Management confirmed consolidated debt stands at ₹102 crore with cash of ₹23 crore, translating to net debt of ~₹80 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the detailed earnings conference call transcript discussing Q2 and H1 FY27 operating performance and segment updates.
ஏன் இது முக்கியம்Provides insights into sustained operating margin expansion (EBITDA margin at 35%), Poultry Healthcare momentum, and debt levels (~₹80 crore net debt vs ₹407 crore net worth).
📅 குறுகிய காலம்Market sentiment should stay supported by high margin execution and robust 35% EBITDA margins, though the primary results were already reported earlier.
📈 நீண்ட காலம்Growth hinges on ramping up utilization at the newly capitalized BSL-3 facility, expanding H9N2 exports, and stabilizing Africa and Nepal operations.
⚠ அபாய எச்சரிக்கைகள்
Delays in Nepal PPR procurement scale
Dependency on government tenders leading to lumpiness in Animal Healthcare revenue
Regulatory tightening lengthening approval cycles for biologicals
👀 கவனிக்க வேண்டியவை
Track export registration timelines for the H9N2 poultry vaccine and monitor the operational turnaround in the Africa and Nepal units in upcoming quarters.
Hester Biosciences Q2 Cons. PAT Up 44% to ₹20.63 Cr; Approves $1M Loan to Africa Unit
Hester Biosciences reported strong Q2 FY27 consolidated performance, with revenue from operations rising 38% YoY to ₹97.91 Cr (INR 979.12 million) and consolidated PAT growing 44% YoY to ₹20.63 Cr. Standalone performance was robust with EBITDA jumping 117% YoY to ₹28.99 Cr and margins expanding by 14% to 35%, driven by a 27% increase in poultry healthcare sales. Additionally, the Board approved an unsecured loan of up to USD 1 million (~₹8.4 Cr) at 9% interest to its wholly-owned subsidiary, Hester Biosciences Africa Limited, for working capital and general purposes.
உச்சம் நம்பிக்கை
என்ன மாறியதுHester Biosciences reported sharp margin and profit expansion in Q2 FY27 financial results and approved a USD 1 million intra-group loan to its African subsidiary.
ஏன் இது முக்கியம்Demonstrates operational turnaround in core Indian poultry biologicals with significant gross margin expansion, while ongoing support is extended to stabilize African operations.
Consolidated Q2 Revenue: INR 979.12 millionConsolidated Q2 PAT: INR 206.31 millionStandalone Q2 EBITDA margin: 35%Loan to Hester Africa: USD 1 millionLoan Interest Rate: 9% per annum
📅 குறுகிய காலம்Market sentiment should react positively to the 38% top-line growth and strong operational margin improvements in Q2 standalone and consolidated results.
📈 நீண்ட காலம்The structural operational turnaround at Hester Africa (backed by the Gates Foundation loan waiver in H1 and commercial expansion) alongside scaling domestic poultry biologicals could drive sustained margin growth.
⚠ அபாய எச்சரிக்கைகள்
Continuing financial support and working capital needs required for Hester Africa subsidiary
Dependency on lumpy government institutional and tender business
👀 கவனிக்க வேண்டியவை
Track the commercial turnaround and revenue ramp-up at Hester Africa following the Gates Foundation debt restructuring and the new USD 1 million credit facility, along with export traction for the poultry division.
CARE Upgrades Hester Biosciences' Long-Term Bank Facilities Rating to 'BBB+; Stable' from 'BBB'
CARE Ratings has upgraded Hester Biosciences' credit ratings across bank facilities totaling ₹113.67 crore. Long-term facilities of ₹48.45 crore (reduced from ₹66.25 crore) were upgraded to CARE BBB+; Stable from CARE BBB; Stable. Long-term / short-term facilities (₹65.00 crore) and short-term facilities (₹0.22 crore) were upgraded to CARE BBB+ / CARE A2 and CARE A2, respectively, driven by operational and financial performance in FY26 and Q1FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுCARE Ratings upgraded Hester Biosciences' long-term bank facilities rating to 'CARE BBB+; Stable' from 'CARE BBB; Stable' and short-term rating to 'CARE A2' from 'CARE A3+'.
ஏன் இது முக்கியம்The rating upgrade signals an improving financial and liquidity profile post-FY26 earnings recovery, potentially lowering future interest costs and improving debt terms.
Total rated bank facilities: ₹113.67 கோடிRated facilities vs TTM revenue: ~34.9%Long-term facilities rated: ₹48.45 கோடிCash credit limit: ₹60.00 கோடிOutstanding foreign currency loan: $4.00 Mn (₹37.87 crore)
📅 குறுகிய காலம்Positive sentiment driver reflecting strengthening creditworthiness and sound balance sheet position.
📈 நீண்ட காலம்Improves financial flexibility and lowers risk premium for prospective debt-funded expansions or working capital scale-up.
⚠ அபாய எச்சரிக்கைகள்
Forex exposure risk on outstanding $4.00 million SBI term loan
Dependency on lumpy institutional tender business in export and regional markets
👀 கவனிக்க வேண்டியவை
Track whether the rating upgrade translates into lower borrowing costs on working capital lines and monitor operating cash flow trends in upcoming quarterly results.
88% Standalone PAT Growth in Q1 FY27; Gates Foundation Waives $7M Debt for Africa
Hester Biosciences reported a strong standalone performance for Q1 FY27 with 14% revenue growth and an 88% surge in PAT, driven by a 48% growth in the Poultry Healthcare division. Gross margins expanded significantly from 69% to 78% due to a favorable product mix and operational efficiencies. A major highlight is the restructuring of the Gates Foundation loan for Hester Africa, reducing the debt from $12 million to $5 million and making it interest-free. Despite standalone strength, consolidated revenue declined 8% due to lumpy institutional orders in Nepal and Africa.
உச்சம் நம்பிக்கை
என்ன மாறியதுHester has successfully improved its standalone margin profile through a better product mix and secured a significant debt waiver that de-risks its international balance sheet.
ஏன் இது முக்கியம்The 900 bps margin expansion and debt reduction significantly improve the company's cash flow outlook and reduce the drag from the African subsidiary on consolidated earnings.
Standalone PAT Growth (YoY): 88%Gross Margin: 78%Debt Reduction (Africa): $7 millionIndia Plant Capex: ₹182 கோடிCapex vs Net Worth: 47.1%Poultry Division Growth: 48%
📅 குறுகிய காலம்The market is likely to react positively to the sharp margin expansion and the one-time exceptional gain from the debt waiver.
📈 நீண்ட காலம்The shift from tender-based business to private commercial markets and the expansion of the biological pipeline are structural positives for long-term valuation.
⚠ அபாய எச்சரிக்கைகள்
Lumpy revenue from government tenders in the Animal Healthcare division
Geopolitical and operating challenges in African markets
👀 கவனிக்க வேண்டியவை
Watch for the operationalization of the ₹182 Cr India plant expansion by March 2026 and the progress toward the FY28 breakeven target for African operations.
Q1 FY27: Standalone PAT up 88% to ₹14.7 Cr; ₹85.3 Cr Exceptional Gain from Debt Reduction
Hester Biosciences reported a strong standalone performance for Q1 FY27 with revenue growing 14% to ₹72.66 Cr and PAT rising 88% to ₹14.71 Cr. The Poultry Healthcare division was the primary driver, growing 48% YoY, while the Animal Healthcare division saw a 50% decline due to government tender delays. A massive consolidated PAT surge of 459% was recorded, primarily due to an ₹85.35 Cr exceptional gain following a debt reduction agreement with the Gates Foundation for Hester Africa. Standalone EBITDA margins expanded significantly to 36% from 21% in the previous year.
உச்சம் நம்பிக்கை
என்ன மாறியதுHester achieved a significant operational turnaround in its standalone poultry business and secured a major debt haircut for its African subsidiary, substantially de-risking its consolidated balance sheet.
ஏன் இது முக்கியம்The debt reduction at Hester Africa removes a significant financial overhang, while the 48% growth in poultry vaccines demonstrates successful market penetration in the private commercial segment, reducing reliance on volatile government tenders.
Standalone Revenue (Q1): ₹72.66 கோடிStandalone PAT (Q1): ₹14.71 கோடிExceptional Gain (Consolidated): ₹85.35 கோடிExceptional Gain vs TTM Revenue: 26.18%Poultry Healthcare Growth: 48%Standalone EBITDA Margin: 36%
📅 குறுகிய காலம்The stock is likely to react positively to the strong standalone margin expansion and the massive bottom-line boost from the debt restructuring, despite the weakness in the animal healthcare segment.
📈 நீண்ட காலம்The structural shift toward a higher-margin private product mix and the de-leveraging of the African unit position the company for more stable earnings growth over the next 2-3 years.
⚠ அபாய எச்சரிக்கைகள்
High volatility in Animal Healthcare revenue due to 50% dependency on government tender timing
Continued variability in institutional orders from Nepal and Africa operations
👀 கவனிக்க வேண்டியவை
Investors should monitor the recovery of the Animal Healthcare tender business in upcoming quarters and the progress of the ₹182 Cr India plant expansion. The sustainability of the 78% gross margin in the absence of lumpy government contracts is a key metric to watch.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Hester Biosciences Sets July 14 as Record Date for INR 11 Per Share Final Dividend
Hester Biosciences Limited has fixed July 14, 2026, as the record date to determine shareholder eligibility for a final dividend of INR 11 per equity share for the financial year. This dividend represents a 110% payout on the face value of INR 10 per share. The distribution is subject to shareholder approval at the company's 39th Annual General Meeting. The record date also serves as the cutoff for determining members entitled to participate in e-voting for the AGM.
முக்கிய அம்சங்கள்
Record date for dividend and AGM e-voting fixed for July 14, 2026.Proposed final dividend of INR 11 per equity share (110% of face value).Face value of the company's equity shares is INR 10 each.Dividend payout is subject to approval at the 39th Annual General Meeting and applicable tax deductions.
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the shares before the ex-dividend date, which typically precedes the July 14 record date. Monitor the 39th AGM outcomes for final dividend declaration and payment timelines.
Hester Biosciences FY26 Consolidated PAT Surges 99% to ₹574.8M; AGM Set for July 21
Hester Biosciences reported a robust financial performance for FY 2025-26, with consolidated profit after tax (PAT) jumping 99% to ₹574.84 million despite a modest 7% revenue growth to ₹3,325.99 million. The company achieved significant margin expansion, with standalone EBITDA rising 56% to ₹871.03 million, driven by a favorable product mix and cost discipline. Key operational milestones include the commercialization of the H9N2 Avian Influenza vaccine and the repurposing of the BSL-3 facility for veterinary use. The company has scheduled its 39th AGM for July 21, 2026, and confirmed a dividend payout ratio of 18%.
முக்கிய அம்சங்கள்
Consolidated PAT grew by 99% YoY to ₹574.84 million, while Standalone PAT rose 64% to ₹521 million.Poultry Healthcare division recorded a strong 24% growth, supported by the launch of the H9N2 Avian Influenza vaccine.Standalone EBITDA increased by 56% to ₹871.03 million, reflecting improved operational efficiencies.The company capitalized its Fill-Finish and BSL-3 facilities, enhancing manufacturing scale-up capabilities.Final dividend payment is scheduled on or after July 28, 2026, for shareholders as of the July 14 cut-off date.
👀 கவனிக்க வேண்டியவை
Investors should note the significant improvement in profitability and margins, suggesting successful cost management and a shift toward higher-margin products. The stock warrants a positive outlook given the successful commercialization of new vaccines and the operational readiness of advanced BSL-3 facilities.
Hester Bio Subsidiary Debt Reduced by USD 7M; Gates Foundation Waives Interest
Hester Biosciences Africa, a wholly-owned subsidiary of Hester India, has successfully renegotiated its loan terms with the Gates Foundation. The outstanding loan facility has been significantly reduced from USD 12 million to USD 5 million, representing a USD 7 million reduction. Furthermore, the lender has waived all accrued interest and converted the remaining balance into a zero-interest loan. These changes, including an extended repayment tenor, will substantially improve the subsidiary's liquidity and reduce the financial pressure on the parent company's corporate guarantee.
முக்கிய அம்சங்கள்
Outstanding loan amount reduced by USD 7 million, from USD 12 million to USD 5 millionComplete waiver of accrued interest amounts by the Gates FoundationFuture interest rate set to 0% on the remaining USD 5 million loan balanceRevision of repayment schedule and extension of loan tenor to improve cash flowCorporate guarantee by Hester India continues for the reduced loan amount
👀 கவனிக்க வேண்டியவை
Investors should view this as a significant positive development that de-leverages the consolidated balance sheet and improves the path to profitability for the African operations. Monitor the subsidiary's operational performance to see if these savings are reinvested into growth.
Hester Biosciences Q4 FY26 PAT Surges 174% Driven by Poultry Segment and Exceptional Gains
Hester Biosciences reported a strong performance for Q4 FY26, with standalone revenue growing 22% and PAT jumping 174% YoY. The Poultry Healthcare division was the primary growth engine, recording 41% growth in Q4, while the consolidated annual PAT doubled, partly aided by exceptional income from a stake sale in Texas Lifesciences. The company has successfully capitalized its new Fill-Finish and BSL-3 facilities and received licenses for the H9N2 Avian Influenza vaccine. Despite earlier delays in government tenders, the company executed the supply of 6.3 crore PPR vaccine doses in the final quarter.
முக்கிய அம்சங்கள்
Standalone Q4 PAT increased by 174% YoY, while consolidated FY26 PAT grew by 100% to reach record levels.Poultry Healthcare division revenue grew 41% in Q4 and 21% for the full financial year FY26.Supplied 6.3 crore doses of PPR vaccine in Q4 FY26, signaling a recovery in the Animal Healthcare tender business.Received marketing and manufacturing licenses for the H9N2 Avian Influenza vaccine, targeting the private commercial market.Capitalized new Fill-Finish and BSL-3 facilities to enhance drug product capacity and operational efficiency.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's transition toward higher-margin biologicals and the scaling of the H9N2 vaccine. The successful capacity expansion and recovery in tender execution provide a positive outlook for FY27.
Hester Biosciences FY26 Consolidated Revenue Hits ₹332.6 Cr; PAT Surges to ₹57.5 Cr
Hester Biosciences reported a strong financial performance for FY 2025-26, with consolidated revenue reaching ₹332.60 crore. The company witnessed a significant recovery in profitability, with consolidated Profit After Tax (PAT) jumping to ₹57.48 crore from ₹21.17 crore in the previous fiscal year. Hester maintains a dominant 35% market share in the Indian poultry vaccine market and is the world's largest supplier of the PPR vaccine. The company is strategically diversifying, with the Animal Healthcare division now contributing 38% to consolidated revenue.
முக்கிய அம்சங்கள்
Consolidated revenue grew to ₹332.60 crore in FY26 compared to ₹311.10 crore in FY25.Consolidated PAT surged to ₹57.48 crore, a substantial increase from ₹21.17 crore in the prior year.Maintains a 35% market share in the Indian poultry vaccine segment as the second-largest manufacturer.Annual manufacturing capacity stands at 8.6 billion doses in India, 1.24 billion in Nepal, and 1.5 billion in Africa.Animal Healthcare division's revenue contribution rose to 38% on a consolidated basis, up from 29% on a standalone basis.
👀 கவனிக்க வேண்டியவை
Investors should view the sharp turnaround in profitability and margin expansion as a positive sign of operational efficiency. The company's leading position in global vaccine banks and expansion into the Petcare segment provide long-term growth visibility.
Hester Biosciences: Promoters Ravin and Bela Gandhi Seek Reclassification of 9.45% Stake to Public
Hester Biosciences has received formal requests from two members of its promoter group, Mr. Ravin Gandhi and Ms. Bela Gandhi, to be reclassified as public shareholders. Mr. Ravin Gandhi holds a 4.74% stake (403,320 shares) and recently resigned from the Board, while Ms. Bela Gandhi holds a 4.71% stake (400,635 shares). Together, they represent 9.45% of the company's voting rights and have declared they no longer exercise management control or hold special rights. The company is now initiating the necessary regulatory steps under SEBI guidelines to process these requests.
முக்கிய அம்சங்கள்
Mr. Ravin Gandhi (4.74% stake) and Ms. Bela Gandhi (4.71% stake) have applied for reclassification from 'Promoter' to 'Public' category.The combined shareholding involved in the reclassification request totals 803,955 equity shares or 9.45% of the company.Mr. Ravin Gandhi resigned from the Board of Directors effective May 12, 2026, to facilitate this transition.Ms. Bela Gandhi confirmed she has had no involvement in company management for the last 12 years.The reclassification is subject to approval from the company's shareholders and the stock exchanges under SEBI Regulation 31A.
👀 கவனிக்க வேண்டியவை
Investors should view this as a standard regulatory restructuring of shareholding; however, monitor if this leads to any future secondary market sales by these individuals once they are classified as public. The move does not impact the company's day-to-day operations or business fundamentals.
Hester Biosciences Q4 PAT Surges 174% to INR 26.38 Cr; Declares INR 11 Dividend
Hester Biosciences reported a robust performance for Q4 FY26, with standalone revenue growing 22% YoY to INR 93.71 crore. Net profit for the quarter saw a significant jump of 174% YoY to INR 26.38 crore, bolstered by an exceptional gain of INR 6.99 crore from a subsidiary sale. The Board has recommended a healthy dividend of INR 11 per share (110% of face value). The Poultry Healthcare segment continues to be the primary growth engine, while the company also confirmed the re-appointment of Ms. Priya Gandhi as Executive Director.
முக்கிய அம்சங்கள்
Standalone Q4 FY26 PAT rose to INR 263.84 million from INR 96.35 million in the previous year's quarter.Full-year FY26 PAT increased by 63.6% to INR 521.00 million compared to INR 318.42 million in FY25.Recommended a final dividend of INR 11 per equity share (110%) for the financial year 2025-26.Poultry Healthcare segment revenue grew 41% YoY in Q4 to INR 650.72 million.Recorded an exceptional gain of INR 69.96 million in Q4 FY26 from the sale of investment in a subsidiary.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant margin improvement and the strong recovery in the poultry segment. The healthy dividend payout and profit growth make this a positive update for long-term shareholders.
Hester Biosciences Recommends ₹11 Dividend; FY26 PAT Surges 64% to ₹521 Million
Hester Biosciences has recommended a final dividend of ₹11 per share for FY26, representing a 110% payout on face value. The company reported a strong financial performance with annual standalone Profit After Tax (PAT) rising 64% to ₹521 million, driven by significant growth in the Poultry Healthcare segment. Quarterly performance was particularly robust, with Q4 PAT jumping to ₹263.84 million from ₹96.35 million in the previous year. Additionally, the board approved the re-appointment of Ms. Priya Gandhi as Executive Director for a three-year term.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹11 per equity share (110%) for the financial year 2025-26.Standalone annual Profit After Tax (PAT) increased by 63.6% YoY to ₹521 million.Q4 FY26 Revenue from operations grew 22% YoY to ₹937.13 million compared to ₹766.72 million.Poultry Healthcare segment revenue grew to ₹2,061.31 million in FY26 from ₹1,665.83 million in FY25.Earnings Per Share (EPS) improved significantly to ₹61.24 for FY26 compared to ₹37.43 in FY25.
👀 கவனிக்க வேண்டியவை
Investors should consider the strong bottom-line growth and healthy dividend payout as a sign of improved operational efficiency. The significant jump in Q4 margins and Poultry segment growth makes this a positive development for long-term holders.
Hester Biosciences Credit Rating Downgraded to CARE BBB; Stable by CARE Ratings
CARE Ratings has downgraded Hester Biosciences' long-term bank facilities from 'CARE BBB+; Stable' to 'CARE BBB; Stable' and short-term ratings from 'A2' to 'A3+'. The downgrade follows a review of the company's FY25 audited and 9MFY26 unaudited financial performance. Management has labeled this downgrade as 'transitional,' pointing towards recent improvements in operating margins, ROCE, and debt coverage ratios post-September 2025. The company maintains adequate liquidity for its debt obligations and has recently secured a manufacturing license for the Avian Influenza H9N2 vaccine.
முக்கிய அம்சங்கள்
Long-term bank facilities downgraded to CARE BBB; Stable from CARE BBB+; StableShort-term bank facilities downgraded to CARE A3+ from CARE A2Total bank facilities rated by CARE Ratings amount to ₹131.47 croreManagement reports improved debt coverage indicators in H1FY26 despite the rating actionCompany holds 75% global market share in PPR vaccine and 35% Indian market share in poultry vaccines
👀 கவனிக்க வேண்டியவை
Investors should exercise caution due to the credit downgrade, which may increase future borrowing costs. Monitor upcoming quarterly results to see if the management's claim of a 'transitional' phase reflects in actual bottom-line improvement and debt reduction.
Hester Biosciences to Divest 43.81% Stake in Texas Lifesciences for INR 92 Million
Hester Biosciences has announced the divestment of a 43.81% equity stake in its subsidiary, Texas Lifesciences Private Limited (TLPL), for a total consideration of INR 92 million. Following the sale to Ticop Life Private Limited, Hester will retain an 11% stake, and TLPL will cease to be a subsidiary. TLPL reported a turnover of INR 285.89 million in FY 2024-25, though over 97% of its sales were internal to Hester. This move allows Hester to unlock capital while maintaining a strategic business relationship with the entity.
முக்கிய அம்சங்கள்
Divesting 43.81% stake out of 54.81% total holding in Texas Lifesciences Private Limited.Total aggregate consideration for the sale is INR 92 million.TLPL's FY 2024-25 turnover was INR 285.89 million with a net worth of INR 134.17 million.Hester will maintain an 11% equity stake and continue business operations with TLPL.The transaction is expected to be completed within three months from March 5, 2026.
👀 கவனிக்க வேண்டியவை
Investors should watch for the impact on consolidated margins since TLPL's internal sales were previously eliminated, and monitor the utilization of the INR 92 million proceeds.
Hester Biosciences Re-appoints Rajiv Gandhi as CEO & MD for 3 Years with 99.54% Approval
Hester Biosciences has announced the successful re-appointment of Mr. Rajiv Gandhi as CEO and Managing Director for a three-year term effective from April 1, 2026. The special resolution was passed via a postal ballot process with an overwhelming 99.54% of valid votes cast in favor. While the promoter group showed 100% support, a significant majority of the small institutional voting block (99.24%) voted against the resolution. This move ensures leadership continuity for the company through March 2029.
முக்கிய அம்சங்கள்
Special resolution for re-appointment of Rajiv Gandhi as CEO & MD passed with 99.54% majority.The new term is effective for three years from April 1, 2026, to March 31, 2029.Total valid votes cast represented 4,075,085 shares, with 4,056,419 votes in favor.Promoter group cast 3,451,082 votes, showing 100% internal support for the leadership.Public institutional holders showed 99.24% dissent, though this represented only 18,570 shares.
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the leadership continuity which supports long-term strategic stability. No immediate action is required as the current management remains at the helm.
Hester Biosciences Proposes Re-appointment of Rajiv Gandhi as CEO & MD for 3 Years
Hester Biosciences has initiated a postal ballot process to seek shareholder approval for the re-appointment of Mr. Rajiv Gandhi as CEO and Managing Director. The proposed tenure is for three years, spanning from April 1, 2026, to March 31, 2029. This move is intended to ensure leadership continuity, and the resolution is being proposed as a Special Resolution. Shareholders can participate in the remote e-voting process from February 8 to March 9, 2026.
முக்கிய அம்சங்கள்
Proposed re-appointment of Mr. Rajiv Gandhi as CEO & Managing Director for a 3-year term.The new term is scheduled to run from April 1, 2026, through March 31, 2029.Remote e-voting period is set for February 8, 2026, to March 9, 2026, with results by March 11.The resolution requires approval as a Special Resolution via postal ballot.The cut-off date for shareholder eligibility was fixed as January 30, 2026.
👀 கவனிக்க வேண்டியவை
This is a routine leadership continuity event for the promoter-led company. Investors should support the resolution to maintain management stability, though no immediate impact on stock price is expected.
Hester Biosciences Q3 FY26: PAT Surges 140% YoY; H9N2 Vaccine License Received
Hester Biosciences reported a strong 140% YoY increase in standalone PAT for Q3 FY26, driven by a favorable product mix and cost discipline. While the Poultry Healthcare division grew by 32% in Q3, the Animal Healthcare division saw a 38% decline due to timing delays in government-led immunization programs. The company achieved a major regulatory milestone by receiving manufacturing licenses for the H9N2 Avian Influenza vaccine and successfully capitalized its fill/finish facility, doubling its drug product capacity.
முக்கிய அம்சங்கள்
Standalone PAT increased by 140% YoY in Q3 FY26, supported by improved operational discipline.Poultry Healthcare division revenue grew 32% in Q3 and 17% over the 9-month period.Received marketing and manufacturing licenses for the H9N2 Avian Influenza vaccine post-quarter end.Capitalized a new fill/finish facility from the INR 182 crore CWIP, doubling drug product capacity.Animal Healthcare revenue declined 38% in Q3 due to tender delays, with recovery expected in Q4 FY26.
👀 கவனிக்க வேண்டியவை
Investors should focus on the upcoming launch of the H9N2 vaccine and the resumption of government immunization tenders in Q4. The doubling of manufacturing capacity positions the company for significant scale-up in both domestic and export markets.
Hester Biosciences Q3 Standalone PAT Jumps 140% to ₹106.7M; Poultry Division Grows 32%
Hester Biosciences reported a robust standalone performance for Q3 FY26, with PAT surging 140% YoY to ₹106.69 million on a 12% revenue increase. The growth was primarily driven by the Poultry Healthcare division, which grew 32%, while the Animal Healthcare division faced a 38% decline due to delayed government tenders. Consolidated PAT for the quarter fell 18% to ₹93.10 million, largely due to losses in the African subsidiary. However, the company has doubled its drug product capacity and expects a strong Q4 as national immunization programs resume.
முக்கிய அம்சங்கள்
Standalone Q3 PAT rose 140% to ₹106.69 million, while standalone revenue grew 12% to ₹703.54 million.Poultry Healthcare division delivered 32% growth in Q3, supported by a new H9N2 Avian Influenza vaccine license.Animal Healthcare revenue declined 38% due to deferred government orders, which are scheduled to commence in February 2026.Consolidated 9M FY26 PAT stands at ₹409.37 million, representing a 50% growth over the previous year.Capitalized a new fill-finish facility during the quarter, effectively doubling the company's drug product capacity.
👀 கவனிக்க வேண்டியவை
Investors should view the standalone margin expansion and poultry segment growth as positive indicators of operational efficiency. The temporary dip in animal healthcare revenue is expected to reverse in Q4, making the current performance a strong base for year-end results.
Hester Biosciences Q3 Standalone PAT Surges 140% YoY to ₹106.7 Mn; CEO Re-appointed
Hester Biosciences delivered a robust standalone performance for Q3 FY26, with Net Profit jumping 140% YoY to ₹106.69 million. Standalone revenue grew by 12% YoY, driven primarily by a 32% growth in the Poultry Healthcare segment. However, consolidated PAT declined by 18% YoY to ₹93.10 million, largely due to a sharp reduction in 'Other Income' compared to the previous year. The board also confirmed the re-appointment of founder Rajiv Gandhi as CEO and Managing Director for a three-year term starting April 2026.
முக்கிய அம்சங்கள்
Standalone Revenue from Operations increased 12% YoY to ₹703.54 million in Q3 FY26.Standalone Net Profit (PAT) rose 140% YoY to ₹106.69 million from ₹44.39 million.Poultry Healthcare segment revenue grew 32% YoY to ₹513.02 million.Consolidated PAT fell 18% YoY to ₹93.10 million, impacted by lower other income of ₹6.69 million vs ₹78.09 million YoY.Mr. Rajiv Gandhi re-appointed as CEO & Managing Director for 3 years effective April 1, 2026.
👀 கவனிக்க வேண்டியவை
Investors should take note of the strong operational recovery in the standalone business and the significant growth in the poultry segment. The re-appointment of the founder-CEO ensures leadership continuity, making the stock a 'Watch' for sustained margin improvement.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
